D-Limonene Gelcaps

Phase 1Small molecule

SStanford University

D-Limonene Gelcaps is one of 6 small molecule programs targeting Xerostomia. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

XerostomiaRecruiting

XerostomiaPhase 1

Recruiting

Competition

Competitive Landscape

7 competitors in Xerostomia

#DrugCompanyPhaseTrials

Isopto Carpine

AAdvanz Pharma

Approved

3 2

Decadron

AAspen Global Incorporated

Approved

1 3

Ethyol

LLegacy Health System

Approved

—4

Evoxac

CCosette Pharmaceuticals, Inc.

Approved

1 5

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 1

1 6

D-Limonene Gelcaps

SStanford University

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2028

Phase 1Recruiting

Xerostomia

NCT04392622

Clinical

Trials by Indication[1]

Xerostomia1 trial

A Phase I Study of d-Limonene With Concurrent Radiation and Platinum Based Chemotherapy for Xerostomia Prevention in Locally Advanced Head and Neck Squamous Cell Carcinoma (HNSCC)

Recruiting·SStanford University·Phase 1·NCT04392622·40 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for D-Limonene Gelcaps. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — D-Limonene Gelcaps compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for D-Limonene Gelcaps. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Stanford University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: SStanford University

D-Limonene Gelcaps

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2028

Trials by Indication[1]

Xerostomia1 trial

References

Drug Info

Quick Facts

Related News